{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T06:25:09Z","timestamp":1764570309233},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1016\/j.yebeh.2005.07.017","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T09:03:55Z","timestamp":1127207035000},"page":"375-382","source":"Crossref","is-referenced-by-count":18,"title":["Long-term safety and tolerability of oxcarbazepine in children: A review of clinical experience"],"prefix":"10.1016","volume":"7","author":[{"given":"Blaise F.D.","family":"Bourgeois","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2005.07.017_bib1","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1212\/WNL.51.5_Suppl_4.S8","article-title":"Treatment of seizures and epilepsy in children and adolescents","volume":"51","author":"Pellock","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2005.07.017_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1056-4993(03)00029-4","article-title":"Psychiatric issues of childhood seizure disorders","volume":"12","author":"Franks","year":"2003","journal-title":"Child Adolesc Psychiatr Clin North Am"},{"key":"10.1016\/j.yebeh.2005.07.017_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1525-5050(03)00022-2","article-title":"Neuropsychiatric aspects of epilepsy in children","volume":"4","author":"Dunn","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2005.07.017_bib4","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1440-1754.2003.00270.x","article-title":"The health-related quality of life of childhood epilepsy syndromes","volume":"39","author":"Sabaz","year":"2003","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.yebeh.2005.07.017_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4065\/78.3.359","article-title":"Therapeutics in pediatric epilepsy: Part 1. The new antiepileptic drugs and the ketogenic diet","volume":"78","author":"Jarrar","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.yebeh.2005.07.017_bib6","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1542\/peds.104.5.1106","article-title":"Managing pediatric epilepsy syndromes with new antiepileptic drugs","volume":"104","author":"Pellock","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.yebeh.2005.07.017_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-33046","article-title":"Some common issues in the use of antiepileptic drugs","volume":"22","author":"Asconape","year":"2002","journal-title":"Semin Neurol"},{"key":"10.1016\/j.yebeh.2005.07.017_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0920-1211(97)00024-7","article-title":"A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy","volume":"27","author":"Bill","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2005.07.017_bib9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(95)90581-2","article-title":"For the UK Lamotrigine\/Carbamazepine Monotherapy Trial Group. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy","volume":"345","author":"Brodie","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2005.07.017_bib10","doi-asserted-by":"crossref","unstructured":"Chadwick DW, Anhut H, Greiner MJ, et al. for the International Gabapentin Monotherapy Study Group 945-77. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology 1998;51:1282\u20138.","DOI":"10.1212\/WNL.51.5.1282"},{"key":"10.1016\/j.yebeh.2005.07.017_bib11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0920-1211(96)01013-3","article-title":"A double-blind controlled clinical trial: Oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy","volume":"26","author":"Christe","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2005.07.017_bib12","doi-asserted-by":"crossref","unstructured":"Dam M, Ekberg R, L\u00f8yning Y, Waltimo O, Jakobsen K. for the Scandinavian Oxcarbazepine Study Group. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3:70\u20136.","DOI":"10.1016\/0920-1211(89)90070-3"},{"key":"10.1016\/j.yebeh.2005.07.017_bib13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0404.2003.00093.x","article-title":"Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy","volume":"107","author":"Privitera","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2005.07.017_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0920-1211(97)00025-9","article-title":"A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy","volume":"27","author":"Guerreiro","year":"1997","journal-title":"Epilepsy Res"},{"issue":"Suppl. 2","key":"10.1016\/j.yebeh.2005.07.017_bib15","first-page":"A391","article-title":"Safety and efficacy of oxcarbazepine 1200mg\/day in patients with recent onset partial epilepsy","volume":"52","author":"Sachdeo","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2005.07.017_bib16","first-page":"146","article-title":"Oxcarbazepine (Trileptal) efficacy and tolerability in children with partial seizures","volume":"10","author":"Lundgren","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.yebeh.2005.07.017_bib17","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1212\/WNL.52.4.732","article-title":"Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures","volume":"52","author":"Schachter","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2005.07.017_bib18","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1212\/WNL.54.12.2245","article-title":"Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial","volume":"54","author":"Beydoun","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2005.07.017_bib19","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1212\/WNL.57.5.864","article-title":"Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures","volume":"57","author":"Sachdeo","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2005.07.017_bib20","doi-asserted-by":"crossref","unstructured":"Glauser TA, Nigro M, Sachdeo R, et al., for the Oxcarbazepine Pediatric Study Group. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology 2000;54:2237\u201344.","DOI":"10.1212\/WNL.54.12.2237"},{"key":"10.1016\/j.yebeh.2005.07.017_bib21","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1499-1654.2000.001597.x","article-title":"Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy","volume":"41","author":"Barcs","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2005.07.017_bib22","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1177\/0091270004266617","article-title":"Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy","volume":"44","author":"Rey","year":"2004","journal-title":"J Clin Pharm"},{"key":"10.1016\/j.yebeh.2005.07.017_bib23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ana.10190","article-title":"Effects of oxcarbazepine on sodium concentration and water handling","volume":"51","author":"Sachdeo","year":"2002","journal-title":"Ann Neurol"},{"issue":"Suppl. 8","key":"10.1016\/j.yebeh.2005.07.017_bib24","article-title":"Long-term efficacy and safety of oxcarbazepine (Trileptal) combination therapy in patients with refractory partial seizures","volume":"43","author":"Walker","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2005.07.017_bib25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0009-9236(03)00124-3","article-title":"Pharmacokinetic drug interactions in children taking oxcarbazepine","volume":"74","author":"Sallas","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2005.07.017_bib26","first-page":"67","article-title":"A comparison of carbamazepine and oxcarbazepine in partial epilepsies","volume":"41","author":"Dizdarer","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2005.07.017_bib27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1046\/j.1365-2362.2001.00869.x","article-title":"Prevalence and risk of gingival enlargement in patients treated with anticonvulsant drugs","volume":"31","author":"Brunet","year":"2001","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.yebeh.2005.07.017_bib28","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.46.2.465","article-title":"Valproic acid hepatic fatalities: III.U.S. experience since 1986","volume":"46","author":"Bryant","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2005.07.017_bib29","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1046\/j.1528-1157.2002.18502.x","article-title":"Acute pancreatitis coincident with valproate use: a critical review","volume":"43","author":"Pellock","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2005.07.017_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/08830738050200020101","article-title":"Levetiracetam in pediatrics","volume":"20","author":"Vigevano","year":"2005","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2005.07.017_bib31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0920-1211(03)00028-7","article-title":"Topiramate: efficacy and tolerability in children according to epilepsy syndromes","volume":"53","author":"Mikaeloff","year":"2003","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2005.07.017_bib32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1528-1157.1998.tb01411.x","article-title":"The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study","volume":"39","author":"Eriksson","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2005.07.017_bib33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1528-1157.2002.13101.x","article-title":"Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial","volume":"43","author":"Glauser","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2005.07.017_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0920-1211(01)00271-6","article-title":"A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy","volume":"46","author":"Nieto-Barrera","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2005.07.017_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0887-8994(02)00467-8","article-title":"Oxcarbazepine in the treatment of childhood epilepsy","volume":"28","author":"Serdaroglu","year":"2003","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2005.07.017_bib36","first-page":"S104","article-title":"Multicenter study of oxcarbazepine pharmacokinetics and tolerability in children with refractory epilepsy","volume":"50","author":"Dulac","year":"2001","journal-title":"Ann Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2005.07.017_bib37","first-page":"41","article-title":"Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability","volume":"42","author":"Gaily","year":"1998","journal-title":"J Intellect Disabil Res"},{"key":"10.1016\/j.yebeh.2005.07.017_bib38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0920-1211(98)00012-6","article-title":"Hyponatremia induced by oxcarbazepine in children","volume":"30","author":"Borusiak","year":"1998","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2005.07.017_bib39","first-page":"180","article-title":"Oxcarbazepine-induced hyponatremia in children? No routine monitoring of electrolytes necessary","volume":"41","author":"Korn-Merker","year":"2000","journal-title":"Epilepsia"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505005003112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505005003112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,24]],"date-time":"2019-03-24T14:48:58Z","timestamp":1553438938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505005003112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S1525505005003112"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2005.07.017","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}